Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-06-25FDA Approved: COTEMPLA XR-ODT — Supplemental Application (Neos Therapeutics Brands, LLC)
The FDA approved a supplemental application for Cotempla XR-ODT (methylphenidate) by Neos Therapeutics Brands, LLC, for the treatment of att…
-
FDA approval · 2021-06-25FDA Approved: JORNAY PM EXTENDED-RELEASE — Supplemental Application (Ironshore Pharmaceuticals Inc.)
FDA approved a supplemental application for Jornay PM Extended-Release (methylphenidate hydrochloride) from Ironshore Pharmaceuticals Inc.
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride submitted by Granules Pharmaceuticals Inc.
-
FDA label_change · 2021-06-25FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
FDA announces a supplemental application outcome for METHYLIN (methylphenidate hydrochloride) from Shionogi Inc., resulting in a labeling ch…
-
FDA approval · 2021-06-25FDA Approved: APTENSIO XR — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for Aptensio XR (methylphenidate hydrochloride) from Rhodes Pharmaceuticals L.P.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-06-25FDA Approved: QUILLICHEW ER — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for Quillichew ER (methylphenidate hydrochloride) submitted by NextWave Pharmaceuticals, Inc.
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals Inc.)
FDA approves Camber Pharmaceuticals' supplemental application for methylphenidate hydrochloride tablets, providing a new generic option.
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (KVK-Tech, Inc.)
FDA granted supplemental approval for a generic extended-release methylphenidate hydrochloride product from KVK-Tech, Inc.
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride by Rising Pharma Holdings, Inc., effectively authorizing a generic…
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD [Phase 4]
A Phase 4 trial evaluating lisdexamfetamine dimesylate for promoting occupational success in young adults with ADHD has completed with resul…
-
FDA approval · 2021-06-22FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride from Rising Pharma Holdings, Inc., signaling an approved suppl…
-
FDA approval · 2021-06-21FDA Approved: METHYLPHENIDATE HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (KVK-Tech, Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride extended-release from KVK-Tech, Inc., authorizing changes to t…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD [Phase 3]
Phase 3 trial evaluating low-dose viloxazine extended-release for ADHD in adolescents has completed; results posted in 2021.
-
FDA approval · 2021-06-14FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for methylphenidate hydrochloride from SpecGx LLC.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 trial update evaluating safety and efficacy of ADDERALL XR in adolescents with ADHD has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD [Phase 4]
Phase 4 trial comparing ADDERALL XR with STRATTERA in children with ADHD completed.
-
CLINICAL_TRIALS withdrawal · 2021-06-03Clinical Trial Update: Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 trial of SPD489 for ADHD in adolescents aged 13-17 was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 2]
Phase 2 trial update evaluating SPD465 for adults with ADHD has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-02Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD [Phase 3]
Phase 3 trial evaluating low-dose viloxazine extended-release for attention deficit/hyperactivity disorder in children has completed with po…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder [Phase 3]
Phase 3 trial evaluating centanafadine sustained-release tablets for ADHD has completed with results posted in 2021.
-
FDA approval · 2021-04-22FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic product containing four amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate,…
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder [Phase 2, Phase 3]
Clinical trial update for treatment of cannabis use disorder in adults with comorbid ADHD; study completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: CTx-1301 Comparative Bioavailability Study [Phase 1, Phase 2]
Clinical trial update for CTx-1301 reporting comparative bioavailability in ADHD, completed Phase 1 and Phase 2 with results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD [Phase 4]
Phase 4 trial update investigating adjuvant effects of vitamin A and vitamin D supplementation in children with ADHD.
-
FDA approval · 2021-04-02FDA Approved: QELBREE — Original Application (Supernus Pharmaceuticals, Inc)
FDA approved QELBREE (viloxazine hydrochloride) through an original NDA from Supernus Pharmaceuticals, Inc. for the treatment of attention-d…